Piramal Pharma Solutions achieves global nitrosamine compliance, strengthening patient safety

Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight

Piramal Pharma posts Q2 FY26 consolidated loss at Rs. 99.22 Cr

Piramal Pharma has reported total income of Rs. 2,109.32 crore during the period ended September 30, 2025

Piramal Pharma reports Q1 FY26 consolidated loss at Rs. 81.70 Cr

Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025

Piramal Pharma completes USFDA inspection of Aurora facility with Zero Form-483 observations

Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025

USFDA issues Form-483 for Piramal Pharma's facility at Turbhe

Observations are largely around improvement of procedures and practices

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business

Piramal Critical Care announces US launch of Chlorpromazine Hydrochloride for Injection

The launch of Chlorpromazine Hydrochloride for Injection is the latest in a series of recent product launches from Piramal Critical Care

Sai Ramana Ponugoti appointed as CEO, ICH of Piramal Pharma

Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.

Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr

Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024